Retatrutide vs Tirzepatide — at a glance

Tirzepatide is the current commercial heavyweight in the GLP-1 class — dual GLP-1 / GIP agonist, ~22.5% mean weight loss at 15 mg over 72 weeks. Retatrutide is the next-generation triple agonist coming up the pipeline — GLP-1 / GIP / glucagon, ~24% mean weight loss at 12 mg over 48 weeks. The headline question is whether the third receptor is worth the early-stage uncertainty.

Property	Tirzepatide	Retatrutide
Mechanism	Dual GLP-1 / GIP agonist	Triple GLP-1 / GIP / glucagon agonist
Brand names	Mounjaro, Zepbound (approved)	None (investigational)
Regulatory status	FDA / EMA approved for T2D + obesity	Phase 3 trials ongoing
Standard dose ladder	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg	1 → 2 → 4 → 8 → 12 mg
Frequency	Once weekly SubQ	Once weekly SubQ
Plasma half-life	~5 days	~6 days
Trial weight loss	~22.5% (SURMOUNT-1, 15 mg, 72 wk)	~24% (Phase 2, 12 mg, 48 wk)
Trial size (key arm)	2539 participants (SURMOUNT-1)	338 participants (Phase 2)
Years of safety data	~5 (post-trial + clinical)	~2 (trial only)
Research-grade availability	Widely available	Available, more limited supply

Mechanism — why a third receptor matters

Tirzepatide hits GLP-1 (insulin secretion + appetite + gastric emptying) and GIP (insulin secretion + possible appetite buffering). Retatrutide hits both of those plus the glucagon receptor.

Glucagon activation sounds wrong for weight loss — glucagon is the hormone that raises blood sugar. But the metabolic story is more interesting: glucagon also increases energy expenditure (it tells the liver to release glucose and the body to use it as fuel) and lipolysis (fat mobilisation). The risk with pure glucagon stimulation would be hyperglycaemia. But because Retatrutide simultaneously stimulates GLP-1 (which boosts insulin), the glucose-raising effect is buffered. The net is appetite suppression (from GLP-1) plus increased energy burn (from glucagon).

If Tirzepatide is “eat less + slight metabolic boost,” Retatrutide is “eat less + meaningful metabolic boost.” The trial data shows this — Retatrutide produces slightly higher heart rates at top doses (a sign of increased energy expenditure) and somewhat larger weight loss per mg.

Efficacy — the headline numbers

Tirzepatide: SURMOUNT-1 (Phase 3, 2539 participants, 72 weeks). At 15 mg: 22.5% mean weight loss. At 10 mg: 19.5%. At 5 mg: 15.0%.

Retatrutide: Phase 2 trial (338 participants, 48 weeks, Lilly 2023). At 12 mg: 24.2% mean weight loss. At 8 mg: 22.8%. At 4 mg: 17.5%.

Two important caveats: Retatrutide’s trial was shorter (48 vs 72 weeks), and weight-loss curves were still trending downward at trial end — meaning the 48-week numbers likely understate the 72-week potential. Real comparison numbers won’t be available until the Phase 3 Retatrutide trial (SURMOUNT-5 equivalent) finishes.

Side effects — same family, slightly different intensity

Effect	Tirzepatide	Retatrutide
Nausea	30–35%	35–45% (higher doses)
Diarrhoea	20%	25%
Heart-rate elevation	~3–5 bpm at maintenance	~5–10 bpm at maintenance
Energy / “warmth”	Sometimes increased	More consistently increased
Pancreatitis (rare)	Boxed warning	Watching closely in trials

The heart-rate elevation is the signature Retatrutide difference. It’s from the glucagon arm — same reason for the warmth / energy reports. For most research participants this isn’t problematic. For anyone with existing cardiovascular concerns, it’s a flag worth discussing with a clinician before any GLP-1-class research.

What “investigational” means in practice

Tirzepatide has FDA and EMA approval. There’s a clear regulatory framework, robust pharmacovigilance, and a large clinical user base. Side effects that show up in 1-in-10,000 patients are starting to be visible.

Retatrutide doesn’t have that yet. Phase 2 data is published and clean, Phase 3 trials are recruiting / running, but rare adverse events haven’t had time to accumulate. Anyone researching with Retatrutide today is operating closer to the frontier — both the upside and the unknowns are larger.

Switching protocols — Tirzepatide to Retatrutide

• Wait one week after the last Tirzepatide dose. Their half-lives are similar.
• Start Retatrutide at 2 mg — not at an “equivalent” dose. Retatrutide is more potent per mg, so matching by mg risks aggressive side effects.
• Watch heart rate for the first 4 weeks. If resting HR rises >15 bpm from baseline, drop back to 1 mg or hold longer at the current step.
• Re-titrate every 4 weeks as tolerated. Most participants stabilise between 4 mg and 8 mg — pushing to 12 mg is for diminishing-returns territory.

Which one’s right for your research?

Choose Tirzepatide if:

• You want the most-studied option with the longest real-world safety record in this dual-agonist class.
• You’re researching glycaemic control as a primary endpoint — Tirz has the better HbA1c data.
• You prefer regulatory certainty: dosing, side effects, contraindications are all well-mapped.
• Your target weight loss is 15–22% — Tirz delivers this with a known profile.
• You have cardiovascular concerns where heart-rate elevation matters.

Choose Retatrutide if:

• You want maximum effect size and your tolerance can handle the heart-rate signal and the steeper side-effect curve.
• You’re researching metabolic-rate effects, not just appetite suppression — glucagon stimulation differentiates Retatrutide here.
• You’ve plateaued on Tirzepatide at 15 mg and want to push further.
• You’re comfortable operating with Phase 2 data — knowing that rare safety signals may still emerge.

Cost and availability

Tirzepatide is established in both prescription and research-grade supply chains. Per-mg pricing is now competitive with Semaglutide in most UK / EU research markets.

Retatrutide research-grade supply is narrower — fewer reliable vendors, more batch-to-batch variability across the market, and the price-per-mg is currently 30–60% higher than Tirzepatide. That gap should close as Phase 3 progresses and more synthesisers tool up. DR Peps stocks both with the same third-party COA verification.

Frequently asked questions

Can I stack Retatrutide and Tirzepatide?

No useful reason to. Both fully agonise GLP-1 and GIP — stacking them saturates those receptors without adding effect. The unique receptor on Retatrutide is glucagon; the only conceivable “benefit” of stacking would be to add glucagon while running Tirz, which is essentially what Retatrutide solo does anyway.

Does the heart-rate elevation reverse if I stop?

Trial data suggests yes — heart-rate elevation reverses within 4–8 weeks of discontinuation as glucagon receptor stimulation wears off. Long-term cardiac safety hasn’t been formally established yet; that’s one of the things Phase 3 will clarify.

What about Cagrilintide?

Cagrilintide is a different mechanism entirely — amylin analogue, not an incretin. It’s complementary rather than competitive. The CagriSema combination (Cagrilintide + Semaglutide) is the closest thing to a “different way to get to the same place as Retatrutide” — combining appetite suppression mechanisms from two different receptor families.

Will Retatrutide make Tirzepatide obsolete?

Unlikely. Retatrutide’s larger effect comes with a different side-effect profile and cardiovascular signal. For many research applications — particularly where heart-rate elevation matters, or where the 22.5% effect at top-dose Tirz is already sufficient — Tirzepatide will remain the better fit. The two will coexist in the research literature the same way Semaglutide and Tirzepatide currently coexist.

Related

Full compound pages: Retatrutide, Tirzepatide. Adjacent comparison: Semaglutide vs Tirzepatide. Category: Weight Loss & Metabolic Research Compounds. Free PDF: GLP-1 Reconstitution Cheat Sheet.